TTK Healthcare
LIMITED

TTKHC:SEC:GJ:070:20 **August 13, 2020**

BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

SCRIP CODE: 507747

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra East
Mumbai 400 051

SCRIP CODE: TTKHLTCARE

Dear Sirs,

Re : Unaudited Financial Results along with Limited Review Report for the First Quarter ended 30th June, 2020

We are forwarding herewith the Unaudited Financial Results along with the Limited Review Report from the Statutory Auditors of the Company, for the First Quarter ended 30th June, 2020, duly reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective Meetings held today.

Kindly take the above documents on record.

Thanking you

Yours faithfully
For TTK Healthcare Limited

Kalyanaraman

(S KALYANARAMAN)
Wholetime Director & Secretary

Encl. : a/a

Regd. Office : No. 6, Cathedral Road, Chennai - 600 086, INDIA
Phone : 91-44-28116106 - 08, Fax : 91-44-28116387
Email : info@ttkhealthcare.com Website : www.ttkhealthcare.com
CIN : L24231TN1958PLC003647

TTK HEALTHCARE LIMITED

Regd. Office : No.6, Cathedral Road, Chennai 600 086

CIN: L24231TN1958PLC003647 Website: www.ttkhealthcare.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2020

[Prepared in compliance with the Indian Accounting Standards (Ind AS)]

(Rs. in lakhs)

Sl. No.	Particulars	For the Quarter ended			For the Year ended
		(30/06/2020)	(31/03/2020)	(30/06/2019)	(31/03/2020)
		Unaudited	Audited	Unaudited	Audited
I.	Revenue from Operations	11,639.67	13,651.55	17,859.06	64,576.78
II.	Other Income	192.46	274.30	185.70	877.54
III.	**Total Income (I + II)**	**11,832.13**	**13,925.85**	**18,044.76**	**65,454.32**
IV.	Expenses				
	(a) Cost of materials consumed	1,606.88	2,599.24	2,426.48	10,413.09
	(b) Purchase of Stock-in-trade	2,181.23	3,998.26	5,129.05	16,971.40
	(c) Changes in inventories of Finished Goods, Work-in-progress and Stock-in-trade	1,022.57	(1,118.86)	(100.61)	(1,382.37)
	(d) Employee benefits expense	3,567.11	3,184.84	3,754.72	14,394.10
	(e) Finance Costs	62.81	92.83	68.02	326.85
	(f) Depreciation and Amortization Expense	353.46	359.63	354.44	1,437.67
	(g) Other Expenses	3,330.36	4,715.79	5,804.10	21,351.10
	Total Expenses (IV)	**12,124.42**	**13,831.73**	**17,436.20**	**63,511.84**
V.	**Profit / (Loss) before Exceptional Items and Tax (III - IV)**	**(292.29)**	**94.12**	**608.56**	**1,942.48**
VI.	Exceptional Items	-	-	-	-
VII.	**Profit / (Loss) before Tax (V - VI)**	**(292.29)**	**94.12**	**608.56**	**1,942.48**
VIII.	Tax Expense:				
	(1) Current Tax	-	85.00	238.00	585.00
	(2) Deferred Tax	(52.07)	(33.06)	6.63	125.54
IX.	**Profit / (Loss) for the period from Continuing Operations (VII-VIII)**	**(240.22)**	**42.18**	**363.93**	**1,231.94**
X.	Profit / (Loss) from Discontinued Operations	-	-	-	-
XI.	Tax Expense of Discontinued Operations	-	-	-	-
XII.	Profit / (Loss) from Discontinued Operations (after tax) (X -XI)	-	-	-	-
XIII.	**Profit / (Loss) for the period (IX + XII)**	**(240.22)**	**42.18**	**363.93**	**1,231.94**
XIV.	**Other Comprehensive Income:**				
	(A) (i) Items that will not be reclassified subsequently to profit or loss	99.76	(402.70)	(91.89)	(678.28)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	6.16	67.14	(6.40)	54.38
	(B) (i) Items that will be reclassified subsequently to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
XV.	**Total Comprehensive Income for the period (XIII + XIV) [Comprising Profit / (Loss) and Other Comprehensive Income for the period]**	**(134.30)**	**(293.38)**	**265.64**	**608.04**

	Paid-up Equity Share Capital (Face Value Rs.10 per share)		**1,413.03**	**1,413.03**	**1,413.03**	**1,413.03**
	Other Equity as per Balance Sheet of previous accounting year (excluding Revaluation Reserve)		-	-	-	23,044.83
XVI.	**Earnings per Equity Share (For Continuing Operations):**					
	(1)	Basic (in Rs.)	(1.70)	0.30	2.58	8.72
	(2)	Diluted (in Rs.)	(1.70)	0.30	2.58	8.72
XVII.	**Earnings per Equity Share (For Discontinued Operations):**					
	(1)	Basic (in Rs.)	-	-	-	-
	(2)	Diluted (in Rs.)	-	-	-	-
XVIII.	**Earnings per Equity Share (For Continuing and Discontinued Operations):**					
	(1)	Basic (in Rs.)	(1.70)	0.30	2.58	8.72
	(2)	Diluted (in Rs.)	(1.70)	0.30	2.58	8.72

Notes:

(1) The above financial results for the First Quarter ended 30th June, 2020 in respect of TTK Healthcare Limited (the Company) have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on 13th August, 2020 through Video Conferencing.

(2) The Company has considered the possible impact that may arise from CoVID-19, a global pandemic, on the carrying amount of its assets including Property, Plant and Equipment, Inventory and Receivables. In developing the assumptions relating to the impact of possible future uncertainties in global economic conditions because of this pandemic, the Company as at the date of approval of these financial results has used internal and external sources of information including economic forecasts. The Company based on current estimates expects that the carrying amount of the above assets will be recovered, net of provisions established. The Company has also assessed the impact of this whole situation on its Capital and Financial Resources, Profitability, Liquidity Position, Internal Financial Controls, etc. and is of the view that based on its present assessment, this situation does not materially impact these financial results. The impact assessment does not indicate any adverse impact on the ability of the Company to continue as a going concern. However, the impact assessment of CoVID-19 is a continuing process, given the uncertainties associated with its nature and duration. The Company will continue to monitor any material changes to future economic conditions.

(3) The Statutory Auditors of the Company have carried out Limited Review of the above Unaudited Financial Results in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

(4) The figures for the Quarter ended 31st March, 2020 are the balancing figure between audited figures in respect of the full financial year and the published unaudited year to date figures upto the end of the Third Quarter of relevant financial year, which was subjected to Limited Review.

(5) The previous period's / year's figures have been regrouped and reclassfied, wherever necessary to conform to the current period's / year's presentation.

(6) This Statement is also available on the website of BSE Limited (www.bseindia.com), National Stock Exchange of India Limited (www.nseindia.com) and also on the website of the Company (www.ttkhealthcare.com).

For TTK HEALTHCARE LIMITED

T T RAGHUNATHAN
Executive Vice Chairman

Place : **Chennai**
Date : **August 13, 2020**

TTK HEALTHCARE LIMITED
Regd. Office : No.6, Cathedral Road, Chennai 600 086
CIN: L24231TN1958PLC003647 Website: www.ttkhealthcare.com

SEGMENTWISE REVENUE, RESULTS, ASSETS & LIABILITIES FOR THE QUARTER ENDED 30TH JUNE, 2020

(Rs. in lakhs)

Sl. No.		Particulars	For the Quarter ended			For the Year ended
			(30/06/2020)	(31/03/2020)	(30/06/2019)	(31/03/2020)
			Unaudited	Audited	Unaudited	Audited
1.	**Segment Revenue: (Sales and Other Operating Income)**					
	(a)	Pharmaceuticals	4,226.68	4,735.10	6,026.58	23,120.51
	(b)	Consumer Products	3,631.59	3,127.14	6,127.36	18,133.39
	(c)	Medical Devices	270.55	1,077.37	1,199.41	4,523.13
	(d)	Protective Devices	1,464.53	2,428.74	2,293.95	9,974.45
	(e)	Foods	2,040.01	2,277.39	2,180.83	8,773.59
	(f)	Others	6.31	5.81	30.93	51.71
	Total		**11,639.67**	**13,651.55**	**17,859.06**	**64,576.78**
	Less : Inter Segment Revenue		-	-	-	-
	Net Sales / Income from Operations		**11,639.67**	**13,651.55**	**17,859.06**	**64,576.78**
2.	**Segment Results: [Profit (+) / Loss (-) before tax and interest from each segment]**					
	(a)	Pharmaceuticals	147.11	210.59	515.18	2,101.02
	(b)	Consumer Products	762.93	74.25	605.46	1,864.06
	(c)	Medical Devices	(279.01)	95.64	207.38	700.70
	(d)	Protective Devices	(507.73)	178.73	(163.29)	(556.14)
	(e)	Foods	(130.55)	(308.88)	(254.55)	(1,055.47)
	(f)	Others	5.43	4.20	15.75	31.25
	Total		**(1.82)**	**254.53**	**925.93**	**3,085.42**
	Less : Finance Cost		62.81	92.83	68.02	326.85
	Less : Unallocable Expenses (Net of Unallocable Income)		227.66	67.58	249.35	816.09
	Total Profit (+) / Loss (-) before tax		**(292.29)**	**94.12**	**608.56**	**1,942.48**
			As on 30/06/2020	**As on 31/03/2020**	**As on 30/06/2019**	**As on 31/03/2020**
3.	**Segment Assets**					
	(a)	Pharmaceuticals	5,379.36	5,811.37	6,575.60	5,811.37
	(b)	Consumer Products	2,984.58	3,950.36	4,424.77	3,950.36
	(c)	Medical Devices	3,922.86	4,118.46	4,275.66	4,118.46
	(d)	Protective Devices	7,301.55	8,173.71	8,368.60	8,173.71
	(e)	Foods	8,561.51	8,344.19	9,187.44	8,344.19
	(f)	Others	158.96	150.57	144.30	150.57
	Total		**28,308.82**	**30,548.66**	**32,976.37**	**30,548.66**
	Unallocated		18,846.42	18,177.72	17,015.82	18,177.72
	Total Assets		**47,155.24**	**48,726.38**	**49,992.19**	**48,726.38**

4.	**Segment Liabilities**					
	(a)	Pharmaceuticals	5,394.77	5,524.74	6,248.87	5,524.74
	(b)	Consumer Products	4,810.10	5,123.40	5,639.67	5,123.40
	(c)	Medical Devices	1,196.11	1,048.28	971.99	1,048.28
	(d)	Protective Devices	1,668.42	2,160.83	1,952.05	2,160.83
	(e)	Foods	1,831.80	1,358.36	1,169.33	1,358.36
	(f)	Others	137.88	135.00	144.74	135.00
	Total		**15,039.08**	**15,350.61**	**16,126.65**	**15,350.61**
	Unallocated		7,351.17	8,476.49	8,456.93	8,476.49
	Total Liabilities		**22,390.25**	**23,827.10**	**24,583.58**	**23,827.10**

Notes:

1. Segments have been identified in line with the Indian Accounting Standard on Segment Reporting (Ind AS 108) based on review of performance by the Top Management.

2. Details of products included in each of the Segments are as below :

   - Pharmaceuticals include products for both Human and Veterinary use.
   - Consumer Products comprise marketing and distribution of Woodward's Gripewater, EVA Range of Cosmetics, Good Home range of Scrubbers, Air Freshners, etc.
   - Medical Devices include Artificial Heart Valves, Orthopaedic Implants, etc.
   - Protective Devices comprise manufacturing and marketing of Male Contraceptives and other allied products.
   - Foods comprise manufacturing and marketing of Food Products.
   - "Others" include Printing and Publishing of Maps and Atlases.

3. The segment-wise revenue, results, assets and liabilities figures relate to respective amounts directly identifiable to each of the segments. The unallocable expenditure includes expenses incurred on common services at the corporate level and also those expenses not identifiable to any specific segment.

4. The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's / year's presentation.

For TTK HEALTHCARE LIMITED

T T RAGHUNATHAN
Executive Vice Chairman

Place : Chennai
Date : August 13, 2020

TTK HEALTHCARE LIMITED

Regd. Office : No.6, Cathedral Road, Chennai 600 086

CIN: L24231TN1958PLC003647 Website: www.ttkhealthcare.com

EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2020

(Rs. in lakhs)

Sl. No.	Particulars	For the Quarter ended			For the Year ended
		(30/06/2020)	(31/03/2020)	(30/06/2019)	(31/03/2020)
		Unaudited	Audited	Unaudited	Audited
1.	Total income from Operations	11,639.67	13,651.55	17,859.06	64,576.78
2.	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary Items)	(292.29)	94.12	608.56	1,942.48
3.	Net Profit / (Loss) for the period before Tax (after Exceptional and / or Extraordinary Items)	(292.29)	94.12	608.56	1,942.48
4.	Net Profit / (Loss) for the period after Tax (after Exceptional and / or Extraordinary Items)	(240.22)	42.18	363.93	1,231.94
5.	Total comprehensive Income for the period [Comprising Profit / (Loss) for the period (after Tax) and Other Comprehensive Income (after Tax)]	(134.30)	(293.38)	265.64	608.04
6.	Equity Share Capital (Face Value of Rs.10/- per share)	1,413.03	1,413.03	1,413.03	1,413.03
7.	Other Equity as per the Balance Sheet of previous accounting year (excluding Revaluation Reserve)	-	-	-	23,044.83
8.	Earnings per share (of Rs.10/- each) (for continuing and discontinued operations)				
	(a) Basic (in Rs.)	(1.70)	0.30	2.58	8.72
	(b) Diluted (in Rs.)	(1.70)	0.30	2.58	8.72

Notes:

(1) The above is an extract of the detailed Statement of Unaudited Financial Results for the First Quarter ended 30th June, 2020, filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

(2) The full financial results for the First Quarter ended 30th June, 2020 are available on the website of BSE Limited (www.bseindia.com), National Stock Exchange of India Limited (www.nseindia.com) and also on the website of the Company (www.ttkhealthcare.com).

(3) These financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on 13th August, 2020 through Video Conferencing.

(4) The Company has considered the possible impact that may arise from CoVID-19, a global pandemic, on the carrying amount of its assets including Property, Plant and Equipment, Inventory and Receivables. In developing the assumptions relating to the impact of possible future uncertainties in global economic conditions because of this pandemic, the Company as at the date of approval of these financial results has used internal and external sources of information including economic forecasts. The Company based on current estimates expects that the carrying amount of the above assets will be recovered, net of provisions established. The Company has also assessed the impact of this whole situation on its Capital and Financial Resources, Profitability, Liquidity Position, Internal Financial Controls, etc. and is of the view that based on its present assessment, this situation does not materially impact these financial results. The impact assessment does not indicate any adverse impact on the ability of the Company to continue as a going concern. However, the impact assessment of CoVID-19 is a continuing process, given the uncertainties associated with its nature and duration. The Company will continue to monitor any material changes to future economic conditions.

(5) The Statutory Auditors of the Company have carried out Limited Review of the above Unaudited Financial Results in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

(6) The figures for the Quarter ended 31st March, 2020 are the balancing figure between audited figures in respect of the full financial year and the published unaudited year to date figures upto the end of the Third Quarter of relevant financial year, which was subjected to Limited Review.

(7) The previous period's / year's figures have been regrouped and reclassfied, wherever necessary to conform to the current period's/ year's presentation.

For TTK HEALTHCARE LIMITED

T T RAGHUNATHAN
Executive Vice Chairman

Place : Chennai
Date : August 13, 2020

Limited Review Report on Unaudited Quarterly Financial Results

To the Board of Directors of TTK Healthcare Limited

1. We have reviewed the accompanying statement of unaudited financial results of **TTK Healthcare Limited** (the "Company"), for the quarter ended 30th June 2020 ("the Statement"), being submitted by the company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Obligations") which has been initialed by us for identification.

Management's Responsibility

2. This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

Auditor's Responsibility

3. Our responsibility is to issue a report on the Statement based on our review.

   We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410 *'Review of Interim Financial Information performed by the Independent Auditor of the Entity'*, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Conclusion

4. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Obligations, including the manner in which it is to be disclosed,
   or that it contains any material misstatement.

Emphasis of Matter

5. We draw attention to Note 2 to the financial results, regarding the management's impairment assessment of property, plant and equipment, right of use assets, intangible assets, investments, trade receivables and inventory valuation as at 30th June 2020 being considered as unimpaired /recoverable based on its internal and external sources of information and estimates, and its judgments on implication expected to arise from COVID-19 pandemic. This being an unprecedented event which is difficult to estimate, the actual implications could vary.
   Our conclusion is not modified in respect of the above matter.

PKF SRIDHAR & SANTHANAM LLP FIRM REGN. No. 003990S/S200018 CHENNAI

Tel +91 44 28112985 to 88 • Fax +91 44 28112989 • Email sands@pkfindia.in • www.pkfindia.in
PKF SRIDHAR & SANTHANAM LLP • KRD Gee Gee Crystal • No.91-92 7th Floor • Dr.Radhakrishnan Salai • Mylapore • Chennai • 600004
REGISTRATION NO. WITH ICAI IS 003990S/S200018

Other Matter

6. Attention is drawn to the fact that the figures for the quarter ended 31st March 2020 as reported in these financial results are the balancing figures between audited figures in respect of full financial year and the published unaudited year to date figures up to the end of the third quarter of the relevant financial year which were subject to limited review by us.

Our conclusion is not modified in respect of this matter.

For **PKF Sridhar & Santhanam LLP**
Chartered Accountants
Firm's Registration No. 003990S/S200018

PKF SRIDHAR & SANTHANAM LLP
FIRM REGN. No. 003990S/S200018
CHENNAI

S.Rajeshwari
Partner
Membership No. 024105
Place: Chennai
Date: 13th August 2020
UDIN: 20024105 ~~AAA~~ A BVJE21